Exact Mass: 808.401002

leurosine

C46H56N4O9 (808.4047086)

Leurosine is a vinca alkaloid. Vinleurosine is a natural product found in Catharanthus lanceus and Catharanthus roseus with data available. D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids

Licoricesaponin B2

C42H64O15 (808.4244994)

Licoricesaponin B2 is found in herbs and spices. Licoricesaponin B2 is isolated from roots of Glycyrrhiza uralensis (Chinese licorice). Isolated from roots of Glycyrrhiza uralensis (Chinese licorice). Licoricesaponin B2 is found in herbs and spices.

seglitide

C44H56N8O7 (808.4271746)

PGP(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

Collagen

C36H60N10O11 (808.444281)

It is used as a food additive .

bryostatin 10

C42H64O15 (808.4244994)

Corynecandin

C41H60O16 (808.388116)

Rubiginoside

C38H64O18 (808.4092444)

Enanderinanin J

C44H56O14 (808.3669876)

C42H64O15

C42H64O15 (808.4244994)

divaroside

C42H64O15 (808.4244994)

glaucoside-B

C42H64O15 (808.4244994)

Anabaenopeptin C

C41H60N8O9 (808.448303)

yunganoside I2

C42H64O15 (808.4244994)

Licoricesaponin B2

C42H64O15 (808.4244994)

4鈥樎?Deoxy, 4鈥樎?epimer;B, H2SO4-Vincristine, BAN, INN|Vinepidine, INN

C46H56N4O9 (808.4047086)

Cypridina Biluciferyl

C44H52N14O2 (808.4397452000001)

Abrusoside C

C42H64O15 (808.4244994)

SCHEMBL1814653

C42H64O15 (808.4244994)

3beta-O-[beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyloxyuronic acid]-16-hydroxy-5alpha,14beta-poriferasta-16,24(24(1))-diene-15,23-dione methyl ester|pandaroside J methyl ester

C42H64O15 (808.4244994)

shuangancistrotectorine C

C50H52N2O8 (808.3723472000001)

3-O-beta-D-glucuronopyranosyl gypsogenin 28-O-beta-D-glucopyranoside|beta-D-glucopyranosyl 3)>-3beta-hydroxyolean-12-en-23-al-28-oate|beta-D-glucopyranosyl [beta-D-glucuronopyranosyl-(1 -> 3)]-3beta-hydroxyolean-12-en-23-al-28-oate|gypsogenin 3-O-beta-D-glucuronopyranosyl-28-O-beta-D-glucopyranoside

C42H64O15 (808.4244994)

bottromycin A2 acid|N-[(3S,6S,14R,14aS)-6-tert-butyl-3-isopropyl-14-methyl-1,4,10-trioxododecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-7(8H)-yliden]-3-methyl-L-valyl-(betaS)-N-[(1R)-2-carboxy-1-(1,3-thiazol-2-yl)ethyl]-beta-methyl-L-phenylalanine amide

C41H60N8O7S (808.4305449999999)

3-O-beta-D-glucopyranosyl olean-11,13(18)-diene-23,28-dioic acid 28-O-beta-D-glucopyranoside

C42H64O15 (808.4244994)

bottromycin B2|N-[(3S,6S,14R,14aS)-6-tert-butyl-3-isopropyl-1,4,10-trioxododecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-7(8H)-yliden]-3-methyl-L-valyl-(betaS)-N-[(1R)-3-methoxy-3-oxo-1-(1,3-thiazol-2-yl)propyl]-beta-methyl-L-phenylalanine amide

C41H60N8O7S (808.4305449999999)

neocynapanoside A

C41H60O16 (808.388116)

Vincathicine

C46H56N4O9 (808.4047086)

Roseadine

C46H56N4O9 (808.4047086)

Catharanthamine

C46H56N4O9 (808.4047086)

C38H64O18

C38H64O18 (808.4092444)

Cynapanoside B

C41H60O16 (808.388116)

3beta-hydroxy-18alpha-methoxy-15,20alpha:18,20beta-diepoxy-13,14:14,15-disecopregna-5,12-dien-14-oic acid 16-oxylactone 3-O-alpha-L-oleandropyranosyl-(1?4)-beta-D-digitoxopyranosyl-(1?4)-beta-D-oleandropyranoside|cynanside A

C42H64O15 (808.4244994)

Quinovic acid-3-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyde

C42H64O15 (808.4244994)

11alpha,12alpha-epoxy-3beta-[(O-beta-D-glucuronopyranosyl)oxy]taraxer-14-en-28-oic acid beta-D-glucopyranosyl ester

C42H64O15 (808.4244994)

callipeltin E

C36H60N10O11 (808.444281)

tragopogonoside I

C42H64O15 (808.4244994)

3-O-beta-D-glucopyranosyl olean-9(11),12-diene-23,28-dioic acid 28-O-beta-D-glucopyranoside

C42H64O15 (808.4244994)

F-10748 B1

C41H60O16 (808.388116)

3-O-??-D-Galactopyranosyl-(1鈥樏傗垎2)-??-D-glucuronopyranosyl-gypsogenin

C42H64O15 (808.4244994)

terracinolide F

C40H56O17 (808.3517326000001)

C41H60O16_1-O-{[(4aS,6aS,6bR,9R,10S,11S,12aR)-9-Formyl-10-(beta-D-glucopyranuronosyloxy)-11-hydroxy-6a,6b,9,12a-tetramethyl-2-methylene-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydro-4a(2H)-picenyl]carbonyl}-beta-D-glucopyranose

C41H60O16 (808.388116)

Oleanane -2H, +1O, 1COOH, O-HexA-HexA

C42H64O15 (808.4244994)

Annotation level-3

Bottromycin A2 Acid

C41H60N8O7S (808.4305449999999)

Bottromycin B2

C41H60N8O7S (808.4305449999999)

Deoxoglycyrrhizin

C42H64O15 (808.4244994)

OHODA-PI

C39H69O15P (808.4373853999999)

Vincaleukoblastine,4-deoxy-1,4-epoxy-, (1b)- (9CI)

C46H56N4O9 (808.4047086)

gitaloxin

C42H64O15 (808.4244994)

A cardenolide glycoside that is gitoxin in which the 16beta-hydroxy group has been formylated. D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides

Vinepidine

C46H56N4O9 (808.4047086)

benzene-1,3-dicarboxylic acid,hexanedioic acid,1-hydroxyhexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate,1-isocyanato-1-[(1-isocyanatocyclohexyl)methyl]cyclohexane

C40H60N2O15 (808.399349)

Seglitide

C44H56N8O7 (808.4271746)

Rifamycin,3-[(1-piperazinylimino)methyl]-

C42H56N4O12 (808.3894536)

Dodecanamide, N,N-(9,9,10,10-tetrahydro-9,9,10,10-tetraoxo1,1-bianthracene-4,4-diyl)bis-

C52H60N2O6 (808.4451140000001)

Bryostatin 18

C42H64O15 (808.4244994)

[(1S,3S,5Z,7R,8E,11R,13E,15S,17R,21R,23R,25S)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-25-yl] pentanoate

C42H64O15 (808.4244994)

PGP(i-12:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C38H66O14P2 (808.3927596000001)

PGP(20:4(6E,8Z,11Z,14Z)+=O(5)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C38H66O14P2 (808.3927596000001)

PGP(20:4(5Z,8Z,11Z,13E)+=O(15)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C38H66O14P2 (808.3927596000001)

PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C38H66O14P2 (808.3927596000001)

PGP(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C38H66O14P2 (808.3927596000001)

PGP(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/i-12:0)

C38H66O14P2 (808.3927596000001)

PGP(i-12:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C38H66O14P2 (808.3927596000001)

PGP(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/i-12:0)

C38H66O14P2 (808.3927596000001)

methyl (3R)-3-[[(2S,3S)-2-[[(2S)-2-[[(6S,9S,12S)-6-tert-butyl-2,8,11-trioxo-9-propan-2-yl-1,4,7,10-tetrazabicyclo[10.3.0]pentadec-4-en-5-yl]amino]-3,3-dimethylbutanoyl]amino]-3-phenylbutanoyl]amino]-3-(1,3-thiazol-2-yl)propanoate

C41H60N8O7S (808.4305449999999)

Smgdg O-16:4_18:4

C43H68O12S (808.4431248000001)

Smgdg O-16:3_18:5

C43H68O12S (808.4431248000001)

Smgdg O-18:5_16:3

C43H68O12S (808.4431248000001)

Smgdg O-18:4_16:4

C43H68O12S (808.4431248000001)

[6-[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H68O12S (808.4431248000001)

[6-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H68O12S (808.4431248000001)

[6-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H68O12S (808.4431248000001)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (8E,11E,14E)-heptadeca-8,11,14-trienoate

C42H65O13P (808.416257)

[(2S,3S,6S)-6-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H68O12S (808.4431248000001)

[(2S,3S,6S)-6-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H68O12S (808.4431248000001)

[(2S,3S,6S)-6-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H68O12S (808.4431248000001)

[(2S,3S,6S)-6-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H68O12S (808.4431248000001)

SMGDG O-33:9;O

C42H64O13S (808.4067414)

SMGDG O-34:8

C43H68O12S (808.4431248000001)

SQDG 33:8;O

C42H64O13S (808.4067414)

SQDG 34:7

C43H68O12S (808.4431248000001)

PI O-30:4;O3

C39H69O15P (808.4373853999999)

PI P-18:0/12:3;O3

C39H69O15P (808.4373853999999)

PI P-18:1/12:2;O3

C39H69O15P (808.4373853999999)

PI 18:0/12:3;O2

C39H69O15P (808.4373853999999)

PI 18:1/11:3;O3

C38H65O16P (808.401002)

PI 18:1/12:2;O2

C39H69O15P (808.4373853999999)

PI 22:0/8:3;O2

C39H69O15P (808.4373853999999)

PI 22:1/7:3;O3

C38H65O16P (808.401002)

PI 22:1/8:2;O2

C39H69O15P (808.4373853999999)

PI 22:2/7:2;O3

C38H65O16P (808.401002)

PI 22:2/8:1;O2

C39H69O15P (808.4373853999999)

PI 29:4;O3

C38H65O16P (808.401002)

(2s,3s,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-3-hydroxy-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-6-{[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}oxan-2-yl]methoxy}-6-methyloxane-3,4,5-triol

C38H64O18 (808.4092444)

(2r)-2-[(1r,2r,3as,3bs,7r,9as,9br,11ar)-7-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-2-hydroxy-3a,6,6,9b,11a-pentamethyl-10-oxo-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-5-(2-hydroxypropan-2-yl)-2-methylfuran-3-one

C42H64O15 (808.4244994)

(5r,8s,12s,16s,19s,22r)-12-hydroxy-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4r,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-diene-14,17-dione

C41H60O16 (808.388116)

7-hydroxy-8-{[5-({5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C42H64O15 (808.4244994)

6-{[4-formyl-4,6a,6b,11,11,14b-hexamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C42H64O15 (808.4244994)

(1r,1's,2s,2's,3's,4s,5'r,6s,7s,8r,8'r,9's,11's,13s,13's,14s,14's,15s,15'r,17s,21s)-3'-(acetyloxy)-6,7,13',14'-tetrahydroxy-9,9,16',16'-tetramethyl-7'-oxo-3,5,10',12',22-pentaoxaspiro[heptacyclo[12.9.0.0¹,⁶.0²,¹⁷.0⁴,¹³.0⁸,¹³.0¹⁸,²³]tricosane-21,6'-hexacyclo[9.8.0.0¹,¹⁵.0²,⁸.0⁵,⁹.0⁸,¹³]nonadecan]-18(23)-en-15-yl acetate

C44H56O14 (808.3669876)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl (1r,2r,5r,8r,9r,10s,12r,16r,17r,18r,21r)-16-hydroxy-1,2,17-trimethyl-14-oxo-8,18-bis(prop-1-en-2-yl)-13-oxapentacyclo[10.8.1.0²,¹⁰.0⁵,⁹.0¹⁷,²¹]henicosane-5-carboxylate

C42H64O15 (808.4244994)

methyl 3,4-dihydroxy-6-{[2-hydroxy-1-(5-isopropyl-4-oxohept-5-en-2-yl)-9a,11a-dimethyl-3-oxo-3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

C42H64O15 (808.4244994)

3-o-β-d-galactopyranosyl-(1→2)-β-d-glucu-ronopyranosyl-gypsogenin

C42H64O15 (808.4244994)

{"Ingredient_id": "HBIN009140","Ingredient_name": "3-o-\u03b2-d-galactopyranosyl-(1\u21922)-\u03b2-d-glucu-ronopyranosyl-gypsogenin","Alias": "NA","Ingredient_formula": "C42H64O15","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "8056","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

abrusoside c

C42H64O15 (808.4244994)

{"Ingredient_id": "HBIN014267","Ingredient_name": "abrusoside c","Alias": "NA","Ingredient_formula": "C42H64O15","Ingredient_Smile": "CC1=CCC(OC1=O)C(C)C2CCC3(C2(CCC45C3CCC6C4(C5)CCC(C6(C)C(=O)O)OC7C(C(C(C(O7)CO)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)C","Ingredient_weight": "808.9 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "33","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101616457","DrugBank_id": "NA"}

(1r,1'r,2r,2's,3's,4s,5'r,6r,7s,8r,8'r,9'r,11's,13s,13'r,14s,14's,15s,15'r,17s,21s)-3'-(acetyloxy)-6,7,13',14'-tetrahydroxy-9,9,16',16'-tetramethyl-7'-oxo-3,5,10',12',22-pentaoxaspiro[heptacyclo[12.9.0.0¹,⁶.0²,¹⁷.0⁴,¹³.0⁸,¹³.0¹⁸,²³]tricosane-21,6'-hexacyclo[9.8.0.0¹,¹⁵.0²,⁸.0⁵,⁹.0⁸,¹³]nonadecan]-18(23)-en-15-yl acetate

C44H56O14 (808.3669876)

(4s,5r,7r,8r,13r,16s,19r,22r)-7-hydroxy-8-{[(2s,4r,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C42H64O15 (808.4244994)

2-({3-hydroxy-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]-6-[(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy]oxan-2-yl}methoxy)-6-methyloxane-3,4,5-triol

C38H64O18 (808.4092444)

methyl (2s,3s,4s,5r,6r)-6-{[(3ar,3br,5as,7s,9as,9bs,11as)-2-hydroxy-1-[(2r,5z)-5-isopropyl-4-oxohept-5-en-2-yl]-9a,11a-dimethyl-3-oxo-3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylate

C42H64O15 (808.4244994)

(1s,3s,5z,7r,8e,11r,13e,15s,17r,21r,23r,25s)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl 2,2-dimethylpropanoate

C42H64O15 (808.4244994)

(2s,3s)-2-{[(2s)-2-{[(3s,6s,14as)-6-tert-butyl-1,4-dihydroxy-3-isopropyl-10-oxo-3h,6h,9h,12h,13h,14h,14ah-pyrrolo[1,2-a]1,4,7,10-tetraazacyclododecan-7-yl]amino}-1-hydroxy-3,3-dimethylbutylidene]amino}-n-[(1r)-3-methoxy-3-oxo-1-(1,3-thiazol-2-yl)propyl]-3-phenylbutanimidic acid

C41H60N8O7S (808.4305449999999)

(4s,5r,7r,8r,13r,16s,19r,22r)-7-hydroxy-8-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6s)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C42H64O15 (808.4244994)

12-hydroxy-8-{[5-({4-hydroxy-5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-diene-14,17-dione

C41H60O16 (808.388116)

(4s,5r,8s,13r,16s,19r,22r)-8-{[(2r,3r,4r,5r,6r)-3-hydroxy-5-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C42H64O15 (808.4244994)

(4s,5r,8s,13r,16s,19r,22s)-8-{[(2r,3r,4r,5r,6r)-3-hydroxy-5-{[(2s,4s,5s,6s)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C42H64O15 (808.4244994)

(1s,3s,5z,7r,8e,11r,13z,15s,17r,21r,23r,25s)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl 2,2-dimethylpropanoate

C42H64O15 (808.4244994)

(2e)-n-[1-({1-[2-(n-{[(1-{[3-methoxy-3-oxo-1-(1,3-thiazol-2-yl)propyl]-c-hydroxycarbonimidoyl}-2-phenylpropyl)-c-hydroxycarbonimidoyl]methyl}carbamimidoyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-c-hydroxycarbonimidoyl)-2,2-dimethylpropyl]-4-methylpent-2-enimidic acid

C41H60N8O7S (808.4305449999999)

(2r,3r,4r,5s)-3-{[(2s,3r,4s,5r,6r)-6-{[(2e,4z)-deca-2,4-dienoyloxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-6-[2,4-dihydroxy-6-(hydroxymethyl)phenyl]-5-hydroxy-2-(hydroxymethyl)oxan-4-yl (2e,4e)-7-hydroxy-2,8-dimethyldeca-2,4-dienoate

C41H60O16 (808.388116)

(2s,3s,4s,5r,6r)-3,4-dihydroxy-6-{[(1r,2r,4s,5r,8r,10s,13r,14r,18s,21s)-2-hydroxy-4,5,9,9,13,20,20-heptamethyl-23-oxo-22-oxahexacyclo[19.2.1.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-16-en-10-yl]oxy}-5-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

C42H64O15 (808.4244994)

(2r)-6-amino-2-({[(3s,6s,9s,12s,15r)-3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-12-isopropyl-6,7-dimethyl-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)hexanoic acid

C41H60N8O9 (808.448303)

8-{[3-hydroxy-5-({5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C42H64O15 (808.4244994)

(1s,3r,6s,7r,8r,11s,12s,15r,16r)-6-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-7,12,16-trimethyl-15-[(1s)-1-[(2s)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecane-7-carboxylic acid

C42H64O15 (808.4244994)

(5r,8s,12s,16s,19s,22r)-12-hydroxy-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2r,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-diene-14,17-dione

C41H60O16 (808.388116)

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14br)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-5-{[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid

C42H64O15 (808.4244994)

(4s,5r,7r,8r,13r,16s,19r,22r)-7-hydroxy-8-{[(2s,4s,5r,6r)-5-{[(2s,4r,5r,6s)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C42H64O15 (808.4244994)

6-{[3a-carboxy-8-formyl-5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-3,5-dihydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

C42H64O15 (808.4244994)

(1r,2r,3as,3bs,9br,11ar)-1-[(2r,3s,4e)-2,3-dihydroxy-6-methylhepta-4,6-dien-2-yl]-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,5h,11h-cyclopenta[a]phenanthren-10-one

C41H60O16 (808.388116)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl (1r,2r,5s,8r,9r,10r,12r,16r,17s,18s,21s)-16-hydroxy-1,2,17-trimethyl-14-oxo-8,18-bis(prop-1-en-2-yl)-13-oxapentacyclo[10.8.1.0²,¹⁰.0⁵,⁹.0¹⁷,²¹]henicosane-5-carboxylate

C42H64O15 (808.4244994)

3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl 16-hydroxy-1,2,17-trimethyl-14-oxo-8,18-bis(prop-1-en-2-yl)-13-oxapentacyclo[10.8.1.0²,¹⁰.0⁵,⁹.0¹⁷,²¹]henicosane-5-carboxylate

C42H64O15 (808.4244994)

(3r)-3-{[(2s,3s)-2-{[(2s)-2-{[(3s,6s,14r,14as)-6-tert-butyl-1,4-dihydroxy-3-isopropyl-14-methyl-10-oxo-3h,6h,9h,12h,13h,14h,14ah-pyrrolo[1,2-a]1,4,7,10-tetraazacyclododecan-7-yl]amino}-1-hydroxy-3,3-dimethylbutylidene]amino}-1-hydroxy-3-phenylbutylidene]amino}-3-(1,3-thiazol-2-yl)propanoic acid

C41H60N8O7S (808.4305449999999)

3-({6-[(deca-2,4-dienoyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl}oxy)-6-[2,4-dihydroxy-6-(hydroxymethyl)phenyl]-5-hydroxy-2-(hydroxymethyl)oxan-4-yl 7-hydroxy-2,8-dimethyldeca-2,4-dienoate

C41H60O16 (808.388116)

(1r,2r,3r,4r,6r,8s,9e,12s,13s,14r,15s)-3,4,6,12,13-pentakis(acetyloxy)-4,8,11,11-tetramethyl-14-[(2-methylpropanoyl)oxy]-7,18-dioxo-19-oxatricyclo[13.4.0.0²,⁶]nonadec-9-en-15-yl 2-methylpropanoate

C40H56O17 (808.3517326000001)

3,4-dihydroxy-6-({2-hydroxy-4,5,9,9,13,20,20-heptamethyl-23-oxo-22-oxahexacyclo[19.2.1.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-16-en-10-yl}oxy)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

C42H64O15 (808.4244994)

(2s,3s,4s,5r,6r)-6-{[(3s,4s,4ar,6ar,6bs,8as,12as,14ar,14br)-4-formyl-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C42H64O15 (808.4244994)

methyl 11-(acetyloxy)-12-ethyl-4-[(1z)-1-{16-ethyl-16-hydroxy-3,13-diazatetracyclo[11.2.2.0²,¹⁰.0⁴,⁹]heptadeca-2(10),4,6,8-tetraen-15-yl}-3-methoxy-3-oxoprop-1-en-2-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2(7),3,5,13-tetraene-10-carboxylate

C46H56N4O9 (808.4047086)

6-{[4,4,6a,11,11,12b,13c-heptamethyl-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1h,2h,3h,4ah,5h,6h,8h,9h,10h,12h,12ah,12ch,13ah,13bh-piceno[13,14-b]oxiren-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C42H64O15 (808.4244994)

(2s,3r,4r,5r,6s)-3-{[(2s,3r,4s,5r,6r)-6-{[(2e,4z)-deca-2,4-dienoyloxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-6-[2,4-dihydroxy-6-(hydroxymethyl)phenyl]-5-hydroxy-2-(hydroxymethyl)oxan-4-yl (2e,4e,7s,8r)-7-hydroxy-2,8-dimethyldeca-2,4-dienoate

C41H60O16 (808.388116)

methyl (13r,15s,16r,18s)-13-[(1r,9r,10r,11s,12r,19r)-11-(acetyloxy)-12-ethyl-10-hydroxy-5-methoxy-10-(methoxycarbonyl)-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2(7),3,5,13-tetraen-4-yl]-18-ethyl-17-oxa-1,11-diazapentacyclo[13.4.1.0⁴,¹².0⁵,¹⁰.0¹⁶,¹⁸]icosa-4(12),5,7,9-tetraene-13-carboxylate

C46H56N4O9 (808.4047086)

1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl 2,2-dimethylpropanoate

C42H64O15 (808.4244994)

5-[(6-carboxy-3,4,5-trihydroxyoxan-2-yl)oxy]-3,4-dihydroxy-6-{[10-hydroxy-11-(hydroxymethyl)-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a-dodecahydropicen-3-yl]oxy}oxane-2-carboxylic acid

C42H64O15 (808.4244994)

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6as,6br,8as,10r,11r,12ar,14bs)-10-hydroxy-11-(hydroxymethyl)-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a-dodecahydropicen-3-yl]oxy}-5-{[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid

C42H64O15 (808.4244994)

methyl 4-[11-(acetyloxy)-12-ethyl-10-hydroxy-5-methoxy-10-(methoxycarbonyl)-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2(7),3,5,13-tetraen-4-yl]-1-ethyl-2-oxa-6,16-diazapentacyclo[14.3.1.0³,¹⁸.0⁵,¹³.0⁷,¹²]icosa-5(13),7,9,11-tetraene-4-carboxylate

C46H56N4O9 (808.4047086)

methyl (1r,10s,11r,12r)-11-(acetyloxy)-12-ethyl-4-[(1z)-1-[(1s,15r,16r)-16-ethyl-16-hydroxy-3,13-diazatetracyclo[11.2.2.0²,¹⁰.0⁴,⁹]heptadeca-2(10),4,6,8-tetraen-15-yl]-3-methoxy-3-oxoprop-1-en-2-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2(7),3,5,13-tetraene-10-carboxylate

C46H56N4O9 (808.4047086)

3,4,6,12,13-pentakis(acetyloxy)-4,8,11,11-tetramethyl-14-[(2-methylpropanoyl)oxy]-7,18-dioxo-19-oxatricyclo[13.4.0.0²,⁶]nonadec-9-en-15-yl 2-methylpropanoate

C40H56O17 (808.3517326000001)

(2s,3s,4s,5r,6r)-6-{[(1r,3as,5ar,5br,7ar,8s,9s,11ar,11br,13ar,13br)-3a-carboxy-8-formyl-5a,5b,8,11a-tetramethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-3,5-dihydroxy-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxane-2-carboxylic acid

C42H64O15 (808.4244994)

(2r,3r,4r,5r,6s)-2-{[(2r,3r,4s,5r,6r)-3-hydroxy-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}-6-{[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}oxan-2-yl]methoxy}-6-methyloxane-3,4,5-triol

C38H64O18 (808.4092444)

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6as,6br,8as,10s,11r,12ar,14bs)-10-hydroxy-11-(hydroxymethyl)-4,4,6a,6b,8a,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a-dodecahydropicen-3-yl]oxy}-5-{[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid

C42H64O15 (808.4244994)

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,8as,12as,12bs,12cr,13as,13br,13cs)-4,4,6a,11,11,12b,13c-heptamethyl-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1h,2h,3h,4ah,5h,6h,8h,9h,10h,12h,12ah,12ch,13ah,13bh-piceno[13,14-b]oxiren-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C42H64O15 (808.4244994)

(1s,3s,5z,7s,8e,11r,13z,15r,17r,21r,23s,25r)-1,11,21-trihydroxy-17-[(1s)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl 3-methylbutanoate

C42H64O15 (808.4244994)

(2r,3r,4r,5s,6s)-3-{[(2s,3r,4s,5r,6r)-6-{[(2e,4z)-deca-2,4-dienoyloxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-6-[2,4-dihydroxy-6-(hydroxymethyl)phenyl]-5-hydroxy-2-(hydroxymethyl)oxan-4-yl (2e,4e)-7-hydroxy-2,8-dimethyldeca-2,4-dienoate

C41H60O16 (808.388116)

(1r,2r,3as,3br,5ar,7r,9as,9bs,11ar)-7-{[(2r,4s,5s,6r)-5-{[(2s,4s,5s,6r)-5-{[(2r,4s,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl formate

C42H64O15 (808.4244994)